Clinical Yield of Laboratory Monitoring During Ritlecitinib Treatment for Alopecia Areata: A Prospective Real-World Cohort Study.

Abnormalities were predominantly mild: 97 patients had maximum grade 1 abnormalities, 2 had grade 2 abnormalities, and none had grade 3 or higher abnormalities.

Prior systemic treatment was associated with higher hazard on univariable analysis (HR, 1.52; 95% CI, 1.02-2.28; P = .041), but no independent predictor remained after multivariable adjustment.

LIMITATIONS: Single-center design, Chinese cohort, and incomplete scheduled monitoring.